⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9108301 | 0.78 | THRB (0.40) | — | |
| SCHEMBL23647035 | 0.78 | — | — | |
| SCHEMBL319331 | 0.74 | — | — | |
| SCHEMBL5932821 | 0.72 | THRB (0.35) | — | |
| SCHEMBL314094 | 0.70 | — | — | |
| SCHEMBL3894837 | 0.69 | ALOX15 (0.38) | — | |
| Ethylene Glycol SCHEMBL17292088 | 0.69 | THRB (0.32) | — | |
| SCHEMBL7079419 | 0.67 | THRB (0.35) | — | |
| SCHEMBL6250058 | 0.67 | THRB (0.35) | — | |
| SCHEMBL749805 | 0.67 | THRB (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024013361-A1 | OLIGONUCLEOTIDES FOR ADAR-MEDIATED RNA EDITING AND USE THEREOF | PROQR THERAPEUTICS II B.V. (NL) | 2024-01-18 | — | — | WO | claimed |
| WO-2023152371-A1 | GUIDE OLIGONUCLEOTIDES FOR NUCLEIC ACID EDITING IN THE TREATMENT OF HYPERCHOLESTEROLEMIA | PROQR THERAPEUTICS II B.V. (NL) | 2023-08-17 | — | — | WO | claimed |
| WO-2023107531-A2 | ANTISENSE OLIGONUCLEOTIDE DRUG TARGETS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-15 | — | — | WO | claimed |
| US-11479771-B2 | Antisense oligonucleotides for the treatment of eye disease | PROQR THERAPEUTICS II B.V. (NL) | 2022-10-25 | — | — | US | claimed |
| EP-3918067-A1 | RNA-EDITING OLIGONUCLEOTIDES FOR THE TREATMENT OF USHER SYNDROME | ProQR Therapeutics II B.V. (NL) | 2021-12-08 | — | — | EP | claimed |
| WO-2021130313-A1 | ANTISENSE OLIGONUCLEOTIDES FOR NUCLEOTIDE DEAMINATION IN THE TREATMENT OF STARGARDT DISEASE | PROQR THERAPEUTICS II B.V. (NL) | 2021-07-01 | — | — | WO | claimed |
| US-10889817-B2 | Oligonucleotide therapy for Leber Congenital Amaurosis | PROQR THERAPEUTICS II B.V. (NL) | 2021-01-12 | — | — | US | claimed |
| WO-2020157008-A1 | RNA-EDITING OLIGONUCLEOTIDES FOR THE TREATMENT OF USHER SYNDROME | PROQR THERAPEUTICS II B.V. (NL) | 2020-08-06 | — | — | WO | claimed |
| US-20200181616-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF EYE DISEASE | LABORATOIRES THEA (FR) | 2020-06-11 | — | — | US | claimed |
| US-10612025-B2 | Antisense oligonucleotides for the treatment of eye disease | PROQR THERAPEUTICS II B.V. (NL) | 2020-04-07 | — | — | US | claimed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | claimed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| EP-1358161-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Amgen Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | claimed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | claimed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | claimed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | claimed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | claimed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | claimed |